Sign in
CompletedNo phase

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

Key facts

Who runs it
Beijing Friendship Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
20 Feb 2023
Ended
23 Apr 2024
Type of study
Interventional
Treatments tested
  • CM310
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • ≥18 years, male and female
  • With IGG4-related disease

Who cannot take part

  • Inoculate live vaccine within 4 weeks before screening
  • Treponema pallidum antibody positive in screening period
  • With a history of solid organ or cell transplantation within 6 months before screening
  • Active hepatitis in screening period
  • With other medical or non-medical conditions that are not suitable for the study by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

The group in the trial

  • CM310Treatment being tested

    CM310, subcutaneous

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of an Anti-IL-4Ra as an add-on Therapy in Patients With Relapsed IgG4-related Disease: A Single-arm, Single-centre Clinical Study
Record updated
18 November 2026